Clinical Trial Update: Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating panobinostat for metastatic hormone-refractory prostate cancer has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-06-21